Search Results - "CISPLATIN"

Isoliquiritigenin attenuates cisplatin-induced hearing loss and ototoxicity by activating the Keap1-Nrf2-ARE pathway.

Authors: Chen Y Luo X Deng Y et al.

Source: Free radical biology & medicine [Free Radic Biol Med] 2025 Dec 16; Vol. 241, pp. 599-616. Date of Electronic Publication: 2025 Oct 03.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Science Country of Publication: United States NLM ID: 8709159 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4596 (Electronic) Linking ISSN: 08915849 NLM ISO Abbreviation: Free Radic Biol Med Subsets: MEDLINE

MeSH Terms: Cisplatin*/toxicity , Cisplatin*/adverse effects , NF-E2-Related Factor 2*/metabolism , NF-E2-Related Factor 2*/genetics , NF-E2-Related Factor 2*/agonists , Chalcones*/pharmacology , Kelch-Like ECH-Associated Protein 1*/metabolism , Kelch-Like ECH-Associated Protein 1*/genetics , Hearing Loss*/chemically induced , Hearing Loss*/drug therapy , Hearing Loss*/pathology , Hearing Loss*/metabolism , Hearing Loss*/prevention & control , Hearing Loss*/genetics , Ototoxicity*/drug therapy , Ototoxicity*/pathology , Ototoxicity*/metabolism, Animals ; Mice ; Signal Transduction/drug effects ; Reactive Oxygen Species/metabolism ; Hair Cells, Auditory/drug effects ; Hair Cells, Auditory/pathology ; Hair Cells, Auditory/metabolism ; Apoptosis/drug effects ; Oxidative Stress/drug effects ; Antioxidant Response Elements ; NAD(P)H Dehydrogenase (Quinone)/genetics ; NAD(P)H Dehydrogenase (Quinone)/metabolism ; Male ; Cochlea/drug effects ; Cochlea/pathology ; Mice, Inbred C57BL ; Humans ; Antineoplastic Agents/toxicity

Aloe-emodin mitigates cisplatin-induced acute kidney injury by Nrf2-mediated ferroptosis regulation.

Authors: Dai Q Xiang Y Qiang R et al.

Source: Free radical biology & medicine [Free Radic Biol Med] 2025 Dec 16; Vol. 241, pp. 104-116. Date of Electronic Publication: 2025 Sep 12.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Science Country of Publication: United States NLM ID: 8709159 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4596 (Electronic) Linking ISSN: 08915849 NLM ISO Abbreviation: Free Radic Biol Med Subsets: MEDLINE

MeSH Terms: Cisplatin*/adverse effects , Cisplatin*/toxicity , Ferroptosis*/drug effects , NF-E2-Related Factor 2*/metabolism , NF-E2-Related Factor 2*/genetics , Acute Kidney Injury*/chemically induced , Acute Kidney Injury*/drug therapy , Acute Kidney Injury*/pathology , Acute Kidney Injury*/metabolism , Anthraquinones*/pharmacology, Animals ; Oxidative Stress/drug effects ; Mice ; Male ; Signal Transduction/drug effects ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/toxicity ; Humans ; Mice, Inbred C57BL ; Disease Models, Animal ; Kidney/drug effects ; Kidney/pathology

Glucose transporter protein 1-targeted polymetallic coordination nanopolymer remodeled cisplatin-resistant microenvironment for enhanced chemotherapy of lung cancer.

Authors: Zhang W Wang X Wang P et al.

Source: Journal of colloid and interface science [J Colloid Interface Sci] 2025 Dec 15; Vol. 700 (Pt 2), pp. 138424. Date of Electronic Publication: 2025 Jul 12.

Publication Type: Journal Article

Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 0043125 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-7103 (Electronic) Linking ISSN: 00219797 NLM ISO Abbreviation: J Colloid Interface Sci Subsets: MEDLINE

MeSH Terms: Cisplatin*/pharmacology , Cisplatin*/chemistry , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Lung Neoplasms*/metabolism , Drug Resistance, Neoplasm*/drug effects , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/chemistry , Glucose Transporter Type 1*/metabolism , Glucose Transporter Type 1*/antagonists & inhibitors , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/pathology , Carcinoma, Non-Small-Cell Lung*/metabolism, Humans ; Tumor Microenvironment/drug effects ; Animals ; Mice ; Drug Screening Assays, Antitumor ; Mice, Inbred BALB C ; Mice, Nude ; Cell Proliferation/drug effects ; A549 Cells ; Cell Survival/drug effects ; Particle Size

Effects of drugs covalent binding on DNA: joint use of microRaman spectroscopy and HRTEM imaging.

Authors: Marini M Torre B Bosurgi E et al.

Source: Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy [Spectrochim Acta A Mol Biomol Spectrosc] 2025 Dec 15; Vol. 343, pp. 126606. Date of Electronic Publication: 2025 Jun 25.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9602533 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3557 (Electronic) Linking ISSN: 13861425 NLM ISO Abbreviation: Spectrochim Acta A Mol Biomol Spectrosc Subsets: MEDLINE

MeSH Terms: DNA*/chemistry , DNA*/metabolism , DNA*/ultrastructure , Microscopy, Electron, Transmission*/methods , Cisplatin*/chemistry , Cisplatin*/pharmacology , Cisplatin*/metabolism, Spectrum Analysis, Raman/methods ; Nucleic Acid Conformation/drug effects

Enhancing cisplatin therapy for small cell lung cancer via a dual strategy of combining surufatinib and CD47 blockade.

Authors: Li K Lin Z Wu T et al.

Source: Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2025 Dec 10; Vol. 388 (Pt 1), pp. 114348. Date of Electronic Publication: 2025 Oct 21.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 8607908 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4995 (Electronic) Linking ISSN: 01683659 NLM ISO Abbreviation: J Control Release Subsets: MEDLINE

MeSH Terms: Cisplatin*/administration & dosage , Cisplatin*/therapeutic use , Lung Neoplasms*/drug therapy , Lung Neoplasms*/pathology , Small Cell Lung Carcinoma*/drug therapy , Small Cell Lung Carcinoma*/pathology , CD47 Antigen*/antagonists & inhibitors , CD47 Antigen*/immunology , Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/therapeutic use, Animals ; Humans ; Cell Line, Tumor ; Mice ; Liposomes ; Female ; Mice, Inbred BALB C ; Ferroptosis/drug effects ; Oligopeptides/administration & dosage ; Oligopeptides/chemistry ; Macrophages/drug effects ; Macrophages/immunology

Clinical Efficacy and Safety of Gemcitabine-Cisplatin Combination in Metastatic Gallbladder Cancer: A Prospective Study from North India.

Authors: Dewan A Talwar V Goel V et al.

Source: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2025 Dec 03; Vol. 56 (1), pp. 233. Date of Electronic Publication: 2025 Dec 03.

Publication Type: Journal Article

Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 101479627 Publication Model: Electronic Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE

MeSH Terms: Gallbladder Neoplasms*/drug therapy , Gallbladder Neoplasms*/pathology , Gallbladder Neoplasms*/mortality , Deoxycytidine*/analogs & derivatives , Deoxycytidine*/administration & dosage , Deoxycytidine*/adverse effects , Cisplatin*/administration & dosage , Cisplatin*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Female ; Gemcitabine ; Male ; Middle Aged ; India/epidemiology ; Prospective Studies ; Aged ; Adult ; Prognosis

The effect of intraoperative abdominal pressure on blood platinum levels and early complications during hyperthermic intraperitoneal chemotherapy.

Authors: Kulturoglu MO Aydin F Aslan F et al.

Source: BMC surgery [BMC Surg] 2025 Dec 03; Vol. 25 (1), pp. 584. Date of Electronic Publication: 2025 Dec 03.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100968567 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2482 (Electronic) Linking ISSN: 14712482 NLM ISO Abbreviation: BMC Surg Subsets: MEDLINE

MeSH Terms: Hyperthermic Intraperitoneal Chemotherapy*/adverse effects , Cisplatin*/blood , Cisplatin*/adverse effects , Cisplatin*/administration & dosage , Antineoplastic Agents*/blood , Antineoplastic Agents*/adverse effects , Antineoplastic Agents*/administration & dosage , Postoperative Complications*/epidemiology , Peritoneal Neoplasms*/therapy , Peritoneal Neoplasms*/blood, Humans ; Female ; Male ; Middle Aged ; Adult ; Aged ; Pressure

Plumbagin remodels the tumor immune microenvironment to overcome cisplatin resistance in tongue squamous cell carcinoma via KLF2 activation and ZWINT/NF-κB inhibition.

Authors: Xu Z Xin Y Jiang Q et al.

Source: International immunopharmacology [Int Immunopharmacol] 2025 Dec 03; Vol. 166, pp. 115651. Date of Electronic Publication: 2025 Oct 06.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 100965259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-1705 (Electronic) Linking ISSN: 15675769 NLM ISO Abbreviation: Int Immunopharmacol Subsets: MEDLINE

MeSH Terms: Cisplatin*/pharmacology , Cisplatin*/therapeutic use , Naphthoquinones*/therapeutic use , Naphthoquinones*/pharmacology , Tongue Neoplasms*/drug therapy , Tongue Neoplasms*/immunology , Kruppel-Like Transcription Factors*/metabolism , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use , Carcinoma, Squamous Cell*/drug therapy , Carcinoma, Squamous Cell*/immunology, Animals ; Humans ; Drug Resistance, Neoplasm/drug effects ; NF-kappa B/metabolism ; NF-kappa B/antagonists & inhibitors ; Tumor Microenvironment/drug effects ; Tumor Microenvironment/immunology ; Cell Line, Tumor ; Mice ; Xenograft Model Antitumor Assays ; Signal Transduction/drug effects ; CD8-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/drug effects

Multi-omics revealed GOT1/ALDH3A1 pathway attenuated head and neck squamous cell carcinoma and increased cisplatin sensitivity through ROS induced by mitochondrial dysfunction.

Authors: Liu Z Han B Liu K et al.

Source: Redox report : communications in free radical research [Redox Rep] 2025 Dec; Vol. 30 (1), pp. 2588031. Date of Electronic Publication: 2025 Dec 01.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9511366 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1743-2928 (Electronic) Linking ISSN: 13510002 NLM ISO Abbreviation: Redox Rep Subsets: MEDLINE

MeSH Terms: Cisplatin*/pharmacology , Cisplatin*/therapeutic use , Reactive Oxygen Species*/metabolism , Squamous Cell Carcinoma of Head and Neck*/metabolism , Squamous Cell Carcinoma of Head and Neck*/drug therapy , Squamous Cell Carcinoma of Head and Neck*/genetics , Squamous Cell Carcinoma of Head and Neck*/pathology , Mitochondria*/metabolism , Mitochondria*/drug effects , Head and Neck Neoplasms*/metabolism , Head and Neck Neoplasms*/drug therapy , Head and Neck Neoplasms*/genetics , Head and Neck Neoplasms*/pathology , Aldehyde Dehydrogenase*/metabolism , Aldehyde Dehydrogenase*/genetics, Humans ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Animals ; Apoptosis/drug effects ; Mice ; Antineoplastic Agents/pharmacology ; Drug Resistance, Neoplasm ; Proteomics ; Multiomics

The antioxidant and anti-inflammatory effects of gallic acid and/or cerium oxide nanoparticles synthesized by gamma-irradiation ameliorate cisplatin-induced hepatic injury.

Authors: Saif-Elnasr M Elmalawany AM Abdel-Khalek AF

Source: Archives of physiology and biochemistry [Arch Physiol Biochem] 2025 Dec; Vol. 131 (6), pp. 941-953. Date of Electronic Publication: 2025 May 22.

Publication Type: Journal Article

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 9510153 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-4160 (Electronic) Linking ISSN: 13813455 NLM ISO Abbreviation: Arch Physiol Biochem Subsets: MEDLINE

MeSH Terms: Cisplatin*/adverse effects , Cisplatin*/toxicity , Cerium*/chemistry , Cerium*/pharmacology , Antioxidants*/pharmacology , Antioxidants*/chemistry , Gallic Acid*/pharmacology , Gallic Acid*/chemistry , Chemical and Drug Induced Liver Injury*/pathology , Chemical and Drug Induced Liver Injury*/metabolism , Chemical and Drug Induced Liver Injury*/drug therapy , Chemical and Drug Induced Liver Injury*/prevention & control , Anti-Inflammatory Agents*/pharmacology , Nanoparticles*/chemistry, Animals ; Rats ; Liver/drug effects ; Liver/pathology ; Liver/metabolism ; Gamma Rays ; Male ; Rats, Wistar ; Antineoplastic Agents/adverse effects ; NF-kappa B/metabolism

Rab27b-mediated CAFs derived exosomal miR-22-3p suppresses ferroptosis and promotes cisplatin resistance in osteosarcoma.

Authors: Duan W Niu X Liu Y et al.

Source: Cellular signalling [Cell Signal] 2025 Dec; Vol. 136, pp. 112125. Date of Electronic Publication: 2025 Sep 17.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 8904683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3913 (Electronic) Linking ISSN: 08986568 NLM ISO Abbreviation: Cell Signal Subsets: MEDLINE

MeSH Terms: Osteosarcoma*/drug therapy , Osteosarcoma*/genetics , Osteosarcoma*/metabolism , Osteosarcoma*/pathology , MicroRNAs*/metabolism , MicroRNAs*/genetics , Cisplatin*/pharmacology , Cisplatin*/therapeutic use , Drug Resistance, Neoplasm*/genetics , Drug Resistance, Neoplasm*/drug effects , Ferroptosis*/drug effects , Ferroptosis*/genetics , Exosomes*/metabolism , Exosomes*/genetics , rab GTP-Binding Proteins*/metabolism , rab GTP-Binding Proteins*/genetics , Cancer-Associated Fibroblasts*/metabolism , Cancer-Associated Fibroblasts*/pathology , Bone Neoplasms*/drug therapy , Bone Neoplasms*/genetics , Bone Neoplasms*/metabolism , Bone Neoplasms*/pathology, Humans ; Animals ; PTEN Phosphohydrolase/metabolism ; Cell Line, Tumor ; Mice ; Mice, Nude ; Gene Expression Regulation, Neoplastic

Zebrafish Xenograft Model for Predicting Cisplatin Efficacy in Muscle-Invasive Bladder Cancer.

Authors: Sugino Y Bao X Sekito S et al.

Source: Cancer science [Cancer Sci] 2025 Dec; Vol. 116 (12), pp. 3376-3387. Date of Electronic Publication: 2025 Oct 08.

Publication Type: Journal Article

Journal Info: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE

MeSH Terms: Cisplatin*/pharmacology , Cisplatin*/therapeutic use , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology , Xenograft Model Antitumor Assays*/methods , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use, Animals ; Zebrafish ; Humans ; Mice ; Cell Line, Tumor ; Disease Models, Animal ; Neoadjuvant Therapy ; Female ; Neoplasm Invasiveness

Cisplatin-induced AKI risk stratification and safety of dose reduction in urothelial carcinoma patients with renal impairment.

Authors: Yamamoto S Higa K Kurokawa K et al.

Source: Actas urologicas espanolas [Actas Urol Esp (Engl Ed)] 2025 Dec; Vol. 49 (10), pp. 501864. Date of Electronic Publication: 2025 Oct 11.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier España Country of Publication: Spain NLM ID: 101771154 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2173-5786 (Electronic) Linking ISSN: 21735786 NLM ISO Abbreviation: Actas Urol Esp (Engl Ed) Subsets: MEDLINE

MeSH Terms: Cisplatin*/administration & dosage , Cisplatin*/adverse effects , Acute Kidney Injury*/chemically induced , Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/adverse effects , Carcinoma, Transitional Cell*/drug therapy , Carcinoma, Transitional Cell*/complications , Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/complications, Humans ; Retrospective Studies ; Male ; Female ; Aged ; Middle Aged ; Risk Assessment ; Aged, 80 and over ; Drug Tapering

BCAR3 confers resistance to cisplatin in head and neck squamous cell carcinoma by sustaining TGF-β/SMAD signaling.

Authors: Wang Y Cheng Z Qiao R et al.

Source: Cellular signalling [Cell Signal] 2025 Dec; Vol. 136, pp. 112124. Date of Electronic Publication: 2025 Sep 09.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 8904683 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-3913 (Electronic) Linking ISSN: 08986568 NLM ISO Abbreviation: Cell Signal Subsets: MEDLINE

MeSH Terms: Cisplatin*/pharmacology , Cisplatin*/therapeutic use , Drug Resistance, Neoplasm*/drug effects , Signal Transduction*/drug effects , Squamous Cell Carcinoma of Head and Neck*/drug therapy , Squamous Cell Carcinoma of Head and Neck*/metabolism , Squamous Cell Carcinoma of Head and Neck*/genetics , Squamous Cell Carcinoma of Head and Neck*/pathology , Transforming Growth Factor beta*/metabolism , Head and Neck Neoplasms*/drug therapy , Head and Neck Neoplasms*/metabolism , Head and Neck Neoplasms*/pathology , Head and Neck Neoplasms*/genetics , Smad Proteins*/metabolism, Humans ; Cell Line, Tumor ; Animals ; Mice ; Female ; Mice, Nude ; Smad2 Protein/metabolism ; Apoptosis/drug effects ; Pyrazoles/pharmacology ; Antineoplastic Agents/pharmacology ; Gene Expression Regulation, Neoplastic/drug effects ; Smad4 Protein/metabolism ; Quinolines

Evaluation of factors associated with clinically problematic hiccups in cisplatin-containing treatment with dexamethasone and neurokinin 1 receptor antagonists.

Authors: Saito Y Takekuma Y Sakakibara-Konishi J et al.

Source: International journal of clinical oncology [Int J Clin Oncol] 2025 Dec; Vol. 30 (12), pp. 2504-2511. Date of Electronic Publication: 2025 Nov 05.

Publication Type: Journal Article

Journal Info: Publisher: Springer-Verlag Tokyo Country of Publication: Japan NLM ID: 9616295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1437-7772 (Electronic) Linking ISSN: 13419625 NLM ISO Abbreviation: Int J Clin Oncol Subsets: MEDLINE

MeSH Terms: Hiccup*/chemically induced , Hiccup*/epidemiology , Cisplatin*/adverse effects , Cisplatin*/administration & dosage , Dexamethasone*/administration & dosage , Dexamethasone*/adverse effects , Neurokinin-1 Receptor Antagonists*/administration & dosage , Neurokinin-1 Receptor Antagonists*/adverse effects , Antineoplastic Combined Chemotherapy Protocols*/adverse effects, Humans ; Male ; Female ; Middle Aged ; Aged ; Retrospective Studies ; Risk Factors ; Aprepitant/administration & dosage ; Adult ; Palonosetron ; Isoquinolines/administration & dosage ; Isoquinolines/adverse effects ; Aged, 80 and over ; Quinuclidines/administration & dosage ; Quinuclidines/adverse effects

Innovative strategies for cisplatin desensitization in hyperthermic intraperitoneal chemotherapy of ovarian cancer.

Authors: Villarreal-González R Navarro-Bahena E Cadenas-García D et al.

Source: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2025 Dec; Vol. 31 (8), pp. 1353-1357. Date of Electronic Publication: 2025 Aug 04.

Publication Type: Journal Article; Case Reports

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9511372 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-092X (Electronic) Linking ISSN: 10781552 NLM ISO Abbreviation: J Oncol Pharm Pract Subsets: MEDLINE

MeSH Terms: Cisplatin*/administration & dosage , Cisplatin*/adverse effects , Cisplatin*/therapeutic use , Ovarian Neoplasms*/drug therapy , Ovarian Neoplasms*/therapy , Hyperthermic Intraperitoneal Chemotherapy*/methods , Hyperthermic Intraperitoneal Chemotherapy*/adverse effects , Antineoplastic Agents*/administration & dosage , Antineoplastic Agents*/adverse effects , Desensitization, Immunologic*/methods , Drug Hypersensitivity*/etiology , Drug Hypersensitivity*/therapy, Humans ; Female ; Adult ; Cytoreduction Surgical Procedures ; Carboplatin/adverse effects ; Carboplatin/administration & dosage ; Peritoneal Neoplasms

Extracellular transfer of HuR promotes acquired cisplatin resistance in esophageal cancer cells.

Authors: Cui Y Zhu X Qian L et al.

Source: Cancer biology & therapy [Cancer Biol Ther] 2025 Dec; Vol. 26 (1), pp. 2495999. Date of Electronic Publication: 2025 Apr 23.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101137842 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1555-8576 (Electronic) Linking ISSN: 15384047 NLM ISO Abbreviation: Cancer Biol Ther Subsets: MEDLINE

MeSH Terms: ELAV-Like Protein 1*/metabolism , ELAV-Like Protein 1*/genetics , Esophageal Neoplasms*/drug therapy , Esophageal Neoplasms*/metabolism , Esophageal Neoplasms*/pathology , Esophageal Neoplasms*/genetics , Cisplatin*/pharmacology , Cisplatin*/therapeutic use , Drug Resistance, Neoplasm* , Exosomes*/metabolism, Humans ; Animals ; Mice ; Cell Line, Tumor ; Mice, Nude ; Apoptosis/drug effects ; Xenograft Model Antitumor Assays ; Antineoplastic Agents/pharmacology

Lactobacillus-derived exopolysaccharide enhances localized cisplatin chemotherapy by modulating gut microbiota in colorectal cancer.

Authors: Chen M Zhao F Wang X et al.

Source: International journal of biological macromolecules [Int J Biol Macromol] 2025 Dec; Vol. 332 (Pt 1), pp. 148581. Date of Electronic Publication: 2025 Oct 27.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7909578 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0003 (Electronic) Linking ISSN: 01418130 NLM ISO Abbreviation: Int J Biol Macromol Subsets: MEDLINE

MeSH Terms: Cisplatin*/pharmacology , Cisplatin*/administration & dosage , Cisplatin*/therapeutic use , Gastrointestinal Microbiome*/drug effects , Colorectal Neoplasms*/drug therapy , Colorectal Neoplasms*/microbiology , Colorectal Neoplasms*/pathology , Polysaccharides, Bacterial*/pharmacology , Polysaccharides, Bacterial*/chemistry , Lactobacillus*/chemistry , Antineoplastic Agents*/pharmacology, Animals ; Mice ; Cell Line, Tumor ; Humans ; Hydrogels/chemistry

The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy.

Authors: Li G Che X Wang S et al.

Source: Annals of medicine [Ann Med] 2025 Dec; Vol. 57 (1), pp. 2447403. Date of Electronic Publication: 2025 Jan 06.

Publication Type: Journal Article; Review

Journal Info: Publisher: Informa Healthcare Country of Publication: England NLM ID: 8906388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2060 (Electronic) Linking ISSN: 07853890 NLM ISO Abbreviation: Ann Med Subsets: MEDLINE

MeSH Terms: Antineoplastic Combined Chemotherapy Protocols*/pharmacology , Antineoplastic Combined Chemotherapy Protocols*/therapeutic use , Cisplatin*/pharmacology , Cisplatin*/therapeutic use , Neoplasms*/drug therapy , Neoplasms*/immunology , Tumor Microenvironment*/drug effects , Tumor Microenvironment*/immunology, Humans ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/pharmacology ; Dendritic Cells/immunology ; Dendritic Cells/drug effects ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use

Chemoproteomics-based profiling reveals the targeting molecular mechanism of reversal of cisplatin resistance by baicalin in head and neck squamous cell carcinoma.

Authors: Wu N Yu S Du S et al.

Source: Biochemical pharmacology [Biochem Pharmacol] 2025 Dec; Vol. 242 (Pt 3), pp. 117360. Date of Electronic Publication: 2025 Sep 21.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2968 (Electronic) Linking ISSN: 00062952 NLM ISO Abbreviation: Biochem Pharmacol Subsets: MEDLINE

MeSH Terms: Cisplatin*/pharmacology , Cisplatin*/therapeutic use , Flavonoids*/pharmacology , Flavonoids*/therapeutic use , Drug Resistance, Neoplasm*/drug effects , Drug Resistance, Neoplasm*/physiology , Squamous Cell Carcinoma of Head and Neck*/drug therapy , Squamous Cell Carcinoma of Head and Neck*/metabolism , Head and Neck Neoplasms*/drug therapy , Head and Neck Neoplasms*/metabolism , Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use , Proteomics*/methods, Humans ; Glutathione S-Transferase pi/metabolism ; Glutathione S-Transferase pi/genetics ; Glutathione S-Transferase pi/antagonists & inhibitors ; Animals ; Cell Line, Tumor ; Mice, Nude ; Mice ; Xenograft Model Antitumor Assays/methods